Search hospitals > Georgia > Augusta
Augusta Oncology Associates PC-D'Antignac
Claim this profileAugusta, Georgia 30901
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Colorectal Cancer
38 reported clinical trials
3 medical researchers
Summary
Augusta Oncology Associates PC-D'Antignac is a medical facility located in Augusta, Georgia. This center is recognized for care of Breast Cancer, Breast cancer, Lung Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Augusta Oncology Associates PC-D'Antignac is involved with conducting 38 clinical trials across 33 conditions. There are 3 research doctors associated with this hospital, such as Sharad Ghamande, Vamsi Kota, MD, and Locke J. Bryan.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
PR positive
2Breast Cancer
ER negative
PR negative
ER positive
Top PIs
Sharad GhamandeAugusta University Medical Center2 years of reported clinical research
Expert in Ovarian Cancer
Expert in Breast Cancer
72 reported clinical trials
150 drugs studied
Vamsi Kota, MDAugusta University Medical Center1 year of reported clinical research
Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
11 reported clinical trials
43 drugs studied
Locke J. BryanAugusta University Medical Center6 years of reported clinical research
Studies Lymphoma
Studies Follicular Lymphoma
9 reported clinical trials
20 drugs studied
Clinical Trials running at Augusta Oncology Associates PC-D'Antignac
Breast Cancer
Breast cancer
Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Augusta Oncology Associates PC-D'Antignac?
Augusta Oncology Associates PC-D'Antignac is a medical facility located in Augusta, Georgia. This center is recognized for care of Breast Cancer, Breast cancer, Lung Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Augusta Oncology Associates PC-D'Antignac is involved with conducting 38 clinical trials across 33 conditions. There are 3 research doctors associated with this hospital, such as Sharad Ghamande, Vamsi Kota, MD, and Locke J. Bryan.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.